About US
Contact us
>>Back
Azopharma Refocuses on Core Capabilities & Restructures Management
- Publisher：
- Publication：2009/12/16
|
Azopharma Product Development Group has integrated its services to offer a more streamlined approach to product development. Focus has returned to Azopharma’s core capabilities, including preclinical services, analytical R&D, formulation development, clinical trial manufacturing, drug delivery technologies, and clinical services.
Azopharma is best known for its science, product and R&D innovation, and creativity in solving difficult challenges. By shifting focus back to its core capabilities, Azopharma anticipates significant improvements in quality of service, communication to clients, and timeliness of delivery of projects. To accomplish this goal, major management restructuring has taken place.
Shri Thanedar, PhD, will be Azopharma’s new Chief Executive Officer. Since 1990, Dr. Thanedar has been Chairman and Owner of Azopharma as well as Chemir Analytical Services, a chemical testing company, and has a strong background in chemistry. He has reorganized Azopharma’s expert team to fully leverage their fields of expertise.
Dan Cammarata was appointed Chief Financial Officer in June 2006 and has had an immediate positive impact on Azopharma’s business in finding areas for cost-savings and efficiency. His expertise will sustain growth and profitability in the coming year.
John Gilbert has been named VP of Analytical Services and will direct the teams responsible for method development/validation, QC release, and stability services at both the Florida and Missouri sites.
Robert Buta, VP of Preclinical Services, will continue to be responsible for the preclinical facility, which supports early phase development. Bruce Hardee, VP of Clinical Services, has over 12 years of experience in human clinical operations and program management and will head the clinical facility, which conducts Phase I-III studies.
Dr. Kevin Kane has been appointed VP of Business Development and will drive the emphasis on technical excellence within the sales and contracts teams. Working with Dr. Blair West (Senior VP Technical Affairs) and John McCarty (VP Formulation Sciences), Dr. Kane will promote Azopharma’s Phase I Express development platform.
Dr. Thanedar made other key appointments to the Azopharma team. VP of Formulation and Commercial Manufacturing, Rod Hartwig, will ensure that development and manufacturing programs are executed on time. Melissa Porazzo, VP of Corporate Compliance, will lead the Quality Assurance, Regulatory Affairs, and Program Management teams.
“We will continue to focus on our strengths and will increase attention on the science as well as delivering what we’ve promised to our clients,” said Dr. Thanedar. “Emphasis on our core capabilities will assure the highest quality products and on-target timelines. These modifications will improve both the quality of Azopharma’s work as well as the level of customer service.” |
Source: Web of Drug Delivery Techonology